These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 28692770)

  • 1. Impact of Stopping Tumor Necrosis Factor Inhibitors on Rheumatoid Arthritis Patients' Burden of Disease.
    Ghiti Moghadam M; Ten Klooster PM; Vonkeman HE; Kneepkens EL; Klaasen R; Stolk JN; Tchetverikov I; Vreugdenhil SA; van Woerkom JM; Goekoop-Ruiterman YPM; Landewé RBM; van Riel PLCM; van de Laar MAFJ; Jansen TL;
    Arthritis Care Res (Hoboken); 2018 Apr; 70(4):516-524. PubMed ID: 28692770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stopping Tumor Necrosis Factor Inhibitor Treatment in Patients With Established Rheumatoid Arthritis in Remission or With Stable Low Disease Activity: A Pragmatic Multicenter, Open-Label Randomized Controlled Trial.
    Ghiti Moghadam M; Vonkeman HE; Ten Klooster PM; Tekstra J; van Schaardenburg D; Starmans-Kool M; Brouwer E; Bos R; Lems WF; Colin EM; Allaart CF; Meek IL; Landewé R; Bernelot Moens HJ; van Riel PL; van de Laar MA; Jansen TL;
    Arthritis Rheumatol; 2016 Aug; 68(8):1810-7. PubMed ID: 26866428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing a tapering strategy to the standard dosing regimen of TNF inhibitors in rheumatoid arthritis patients with low disease activity.
    Plasencia C; Wolbink G; Krieckaert CL; Kneepkens EL; Turk S; Jurado T; Martínez-Feito A; Navarro-Compán V; Bonilla G; Villalba A; Peiteado D; Nuño L; Martín-Mola E; Nurmohamed MT; van der Kleij D; Rispens T; Pascual-Salcedo D; Balsa A
    Clin Exp Rheumatol; 2016; 34(4):655-62. PubMed ID: 27214767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of medication withdrawal method on flare-free survival in patients with juvenile idiopathic arthritis on combination therapy.
    Chang CY; Meyer RM; Reiff AO
    Arthritis Care Res (Hoboken); 2015 May; 67(5):658-66. PubMed ID: 25220674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limited value for ultrasonography in predicting flare in rheumatoid arthritis patients with low disease activity stopping TNF inhibitors.
    Lamers-Karnebeek FB; Luime JJ; Ten Cate DF; Teerenstra S; Swen NWAA; Gerards AH; Hendrikx J; van Rooyen EM; Voorneman R; Haagsma C; Basoski N; de Jager M; Ghiti Moghadam M; Efde MN; Goekoop-Ruiterman YPM; van Riel PLCM; Jacobs JWG; Jansen TL
    Rheumatology (Oxford); 2017 Sep; 56(9):1560-1565. PubMed ID: 28595367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.
    Favalli EG; Sinigaglia L; Becciolini A; Grosso V; Gorla R; Bazzani C; Atzeni F; Sarzi Puttini PC; Fusaro E; Pellerito R; Caporali R
    Int J Rheum Dis; 2018 Feb; 21(2):422-430. PubMed ID: 29082659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcomes after disease activity-guided dose reduction of TNF inhibition in rheumatoid arthritis: 3-year data of the DRESS study - a randomised controlled pragmatic non-inferiority strategy trial.
    Bouman CA; van Herwaarden N; van den Hoogen FH; Fransen J; van Vollenhoven RF; Bijlsma JW; Maas AV; den Broeder AA
    Ann Rheum Dis; 2017 Oct; 76(10):1716-1722. PubMed ID: 28606961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Rheumatoid Arthritis With Anti-Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study.
    Choy EH; Bernasconi C; Aassi M; Molina JF; Epis OM
    Arthritis Care Res (Hoboken); 2017 Oct; 69(10):1484-1494. PubMed ID: 28622454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Economic Evaluation of Stopping Versus Continuing Tumor Necrosis Factor Inhibitor Treatment in Rheumatoid Arthritis Patients With Disease Remission or Low Disease Activity: Results From a Pragmatic Open-Label Trial.
    Tran-Duy A; Ghiti Moghadam M; Oude Voshaar MAH; Vonkeman HE; Boonen A; Clarke P; McColl G; Ten Klooster PM; Zijlstra TR; Lems WF; Riyazi N; Griep EN; Hazes JMW; Landewé R; Bernelot Moens HJ; van Riel PLCM; van de Laar MAFJ; Jansen TL;
    Arthritis Rheumatol; 2018 Oct; 70(10):1557-1564. PubMed ID: 29745059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-biomarker disease activity score as a predictor of disease relapse in patients with rheumatoid arthritis stopping TNF inhibitor treatment.
    Ghiti Moghadam M; Lamers-Karnebeek FBG; Vonkeman HE; Ten Klooster PM; Tekstra J; Schilder AM; Visser H; Sasso EH; Chernoff D; Lems WF; van Schaardenburg DJ; Landewe R; Bernelot Moens HJ; Radstake TRDJ; van Riel PLCM; van de Laar MAFJ; Jansen TL;
    PLoS One; 2018; 13(5):e0192425. PubMed ID: 29791439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis.
    Cannon GW; DuVall SL; Haroldsen CL; Caplan L; Curtis JR; Michaud K; Mikuls TR; Reimold A; Collier DH; Joseph GJ; Harrison DJ; Sauer BC
    Adv Ther; 2016 Aug; 33(8):1347-59. PubMed ID: 27352377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for flare and treatment of disease flares during pregnancy in rheumatoid arthritis and axial spondyloarthritis patients.
    van den Brandt S; Zbinden A; Baeten D; Villiger PM; Østensen M; Förger F
    Arthritis Res Ther; 2017 Mar; 19(1):64. PubMed ID: 28320445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis.
    Zhou ZY; Griffith J; Du EX; Chin D; Betts KA; Ganguli A
    Adv Ther; 2016 May; 33(5):807-23. PubMed ID: 27084724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness of TNF-Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF-Blocker Injections in Rheumatoid Arthritis Trial.
    Vanier A; Mariette X; Tubach F; Fautrel B;
    Value Health; 2017 Apr; 20(4):577-585. PubMed ID: 28407999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing the expediency of TNFi in rheumatoid arthritis: offering a TNFi holiday in patients having reached low-disease activity in the maintenance phase.
    van Ingen IL; Lamers-Karnebeek F; Jansen TL
    Expert Opin Biol Ther; 2014 Dec; 14(12):1761-7. PubMed ID: 25366268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of treatment options after conventional DMARDs failure in rheumatoid arthritis.
    Sung YK; Cho SK; Kim D; Choi CB; Won S; Bang SY; Cha HS; Choe JY; Chung WT; Hong SJ; Jun JB; Kim HA; Kim J; Kim SK; Kim TH; Lee HS; Lee J; Lee J; Lee SS; Lee SW; Lee YA; Nah SS; Suh CH; Yoo DH; Yoon BY; Bae SC;
    Rheumatol Int; 2017 Jun; 37(6):975-982. PubMed ID: 28132102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vasodilator function worsens after cessation of tumour necrosis factor inhibitor therapy in patients with rheumatoid arthritis only if a flare occurs.
    Rongen GA; van Ingen I; Kok M; Vonkeman H; Janssen M; Jansen TL
    Clin Rheumatol; 2018 Apr; 37(4):909-916. PubMed ID: 29307093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.
    Favalli EG; Pregnolato F; Biggioggero M; Becciolini A; Penatti AE; Marchesoni A; Meroni PL
    Arthritis Care Res (Hoboken); 2016 Apr; 68(4):432-9. PubMed ID: 26556048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of add-on tacrolimus on methotrexate to maintain clinical remission after rediscontinuation of a tumor necrosis factor inhibitor in rheumatoid arthritis patients who relapsed shortly after discontinuation of the same tumor necrosis factor inhibitor due to clinical remission.
    Naniwa T; Iwagaitsu S; Kajiura M
    Mod Rheumatol; 2017 Jan; 27(1):29-34. PubMed ID: 27143107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tofacitinib with conventional synthetic disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: Patient-reported outcomes from a Phase 3 randomized controlled trial.
    Li Z; An Y; Su H; Li X; Xu J; Zheng Y; Li G; Kwok K; Wang L; Wu Q
    Int J Rheum Dis; 2018 Feb; 21(2):402-414. PubMed ID: 29314645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.